Investing.com - Akoya Biosciences (NASDAQ: AKYA) reported fourth quarter EPS of $-0.22, $0.05 better than the analyst estimate of $-0.27. Revenue for the quarter came in at $26.5M versus the consensus estimate of $26.13M.
Guidance
Akoya Biosciences sees FY 2024 revenue of $114.00M-$118.00M versus the analyst consensus of $116.00M.
Akoya Biosciences's stock price closed at $5.98. It is up 35.60% in the last 3 months and down -49.11% in the last 12 months.
Akoya Biosciences saw 6 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Akoya Biosciences's stock price’s past reactions to earnings here.
According to InvestingPro, Akoya Biosciences's Financial Health score is "fair performance".
Check out Akoya Biosciences's recent earnings performance, and Akoya Biosciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar